Long-Term Efficacy and Safety Profile of Single-Pill Combinations of Telmisartan/Amlodipine in Patients Not Controlled on Amlodipine 5 Mg: Open-Label Follow-Up of Teamsta-5: PP.27.95

Neldam, Steen; Lang, Margreet; Jones, R

doi:10.1097/01.hjh.0000379633.48905.41

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[8][9][10][11][12][13] Where reported, BP control and response rates were significantly higher in telmisartan/ amlodipine recipients than in patients receiving amlodipine or telmisartan monotherapy (table II). [8][9][10][11][12][13] Long-term treatment with telmisartan/amlodipine (plus additional antihypertensive therapy in some patients) resulted in additional clinically meaningful achievement of DBP goals over 36 weeks in follow-up studies [15,16] of two of the trials. [8,11] Does it provide 24-hour control?…”

Section: Initial Therapymentioning

confidence: 99%

“…In 36-week follow-up studies [15,16] of two of the trials in patients not responding to amlodipine monotherapy, [8,11] the incidence of treatment-related peripheral oedema was 5.7 and 5.3 patients per 100 patient-years with telmisartan/ amlodipine 40 mg/5 mg or 80 mg/5 mg per day [15] and 7.9 and 7.1 patients per 100 patient-years with telmisartan/ amlodipine 40 mg/10 mg or 80 mg/10 mg per day. [16] What is its current positioning?…”

Section: Initial Therapymentioning

confidence: 99%

See 1 more Smart Citation

Telmisartan/amlodipine single-pill combination: a guide to its use in hypertension

&NA;

2011

Drugs & Therapy Perspectives

View full text Add to dashboard Cite

Section: Initial Therapymentioning

confidence: 99%

Section: Initial Therapymentioning

confidence: 99%

Telmisartan/amlodipine single-pill combination: a guide to its use in hypertension

&NA;

2011

Drugs & Therapy Perspectives

View full text Add to dashboard Cite

A single-dose, randomized, crossover bioequivalence study of levamlodipine besilate tablets in healthy subjects

Deng,

Yang,

Cheng

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Single-Pill Telmisartan and Amlodipine

Suárez

2011

Drugs

View full text Add to dashboard Cite

Despite the well documented benefits conferred by adequate control of hypertension, the majority of hypertensive patients display suboptimal control and few patients achieve blood pressure (BP) levels <140/90 mmHg. As a consequence, combination therapy will be required in the majority of patients to achieve target BP. Fixed-dose combinations of antihypertensives not only simplify treatment regimens, contributing to enhanced patient adherence, they provide superior BP-lowering efficacy and an improved tolerability profile. Fixed-dose combinations have become the strategy of choice in high-risk patients or those with stage 2-3 hypertension. The combination of a renin-angiotensin system inhibitor (RASI) with a calcium channel blocker (CCB) is a first-line combination that, in addition to its antihypertensive efficacy, reduces oedema, the main adverse effect of the dihydropyridine CCB and the main factor limiting their use. In morbidity/mortality studies, this fixed-dose combination has also demonstrated superiority over a RASI combined with a diuretic. The single-pill combination of telmisartan and amlodipine has been shown to produce a dose-dependent BP-lowering effect significantly greater than that of either agent administered as monotherapy. These findings have been confirmed by ambulatory BP monitoring in patients with stage 1 and 2 hypertension, which demonstrated that single-pill telmisartan/amlodipine provides substantial 24-hour BP-lowering efficacy. A higher proportion of patients achieved 24-hour BP goals of <130/80 mm Hg on combination therapy. The superior efficacy of combination therapy has been demonstrated across a broad range of patients, including those with moderate-to-severe hypertension, diabetes mellitus and obesity. Moreover, combined use of telmisartan and amlodipine reduces the incidence of amlodipine-induced oedema, making it a preferred combination for the treatment of hypertension.

show abstract

Long-Term Efficacy and Safety Profile of Single-Pill Combinations of Telmisartan/Amlodipine in Patients Not Controlled on Amlodipine 5 Mg: Open-Label Follow-Up of Teamsta-5: PP.27.95

Cited by 3 publications

References 0 publications

Telmisartan/amlodipine single-pill combination: a guide to its use in hypertension

Telmisartan/amlodipine single-pill combination: a guide to its use in hypertension

A single-dose, randomized, crossover bioequivalence study of levamlodipine besilate tablets in healthy subjects

Single-Pill Telmisartan and Amlodipine

Contact Info

Product

Resources

About